Alendronic Acid

Alendronic Acid

SCHEMBL3388

NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.O.O.O.[Na+]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

FDPS

The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FDPS known ✓ P14324 18/20 0.96
PDE3A Q14432 2/20 0.70
LMNA P02545 2/20 0.52
ADRB3 P13945 1/20 0.52
PDE4D Q08499 1/20 0.52
GGPS1 O95749 7/20 0.46
CYP3A4 P08684 1/20 0.35
NFKB1 P19838 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alendronic Acid SCHEMBL5973704 1.00 FDPS (0.96) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL536412 1.00 FDPS (0.96) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL204535 1.00 FDPS (0.96) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL5984073 1.00 FDPS (0.96) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL3110183 1.00 FDPS (0.96) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL14840776 0.98 FDPS (0.93) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL177947 0.98 FDPS (0.93) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL2282827 0.98 FDPS (0.93) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL328770 0.98 FDPS (1.00) FDPSPDE3ALMNAADRB3PDE4D
Alendronic Acid SCHEMBL7749180 0.96 FDPS (0.89) FDPSPDE3ALMNAADRB3PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 15651 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005663-A Application of aconite in treating kidney-yang deficiency type osteoporosis 重庆医科大学 2026-05-12 CN claimed
CN-122005953-A Drug mineralized gel and preparation method and application thereof 中国科学院兰州化学物理研究所 2026-05-12 CN claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
CN-121570641-A Hydrogel for repairing osteoporosis bone defect and preparation method thereof 西南交通大学 2026-02-27 CN claimed
EP-3787631-B1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS UNIV EMORY (US) 2025-09-10 EP claimed
US-20250242092-A1 SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS SIO2 MEDICAL PRODUCTS INC (US) 2025-07-31 US claimed
US-12337065-B2 Compositions for treating viral infections and methods for same ACCESS TO ADVANCED HEALTH INSTITUTE (US) 2025-06-24 US claimed
CN-120154943-A Hemodialysis adsorbent, preparation method, hemodialysis adsorption column and blood purification device 上海天佑医院有限公司 2025-06-17 CN claimed
CN-119656381-B Active organic-inorganic composite implant material and preparation method and application thereof 广东粤港澳大湾区黄埔材料研究院 2025-06-13 CN claimed
CN-120022763-A Long-acting reverse osmosis RO membrane filter material and preparation method thereof 四川耐氏环保科技有限公司 2025-05-23 CN claimed
US-5773429-A Drug combination for treating calcium loss FUISZ TECHNOLOGIES LTD. (US) 1998-06-30 US claimed
WO-1998025628-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING ALENDRONATE AND AN AGENT PROMOTING GASTRIC EMPTYING FUISZ TECHNOLOGIES LTD. (US) 1998-06-18 WO claimed
CN-1181008-A Method of lessening the risk of vertebral fractures MARCK & CO INC (US) 1998-05-06 CN claimed
CN-1181012-A Method of lessening the rish of non-vertebral bone fractures MARCK & CO INC (US) 1998-05-06 CN claimed
WO-1998014196-A1 LIQUID ALENDRONATE FORMULATIONS MERCK & CO., INC. (US) 1998-04-09 WO claimed
EP-0824341-A1 PREVENTION OF TOOTH LOSS BY THE ADMINISTRATION OF ALENDRONATE OR ITS SALTS Merck & Co., Inc. (US) 1998-02-25 EP claimed
WO-1997044017-A1 EFFERVESCENT BISPHOSPHONATE FORMULATION MERCK & CO., INC. (US) 1997-11-27 WO claimed
WO-1997029754-A1 TOPICAL BISPHOSPHONATES FOR PREVENTION OF BONE RESORPTION BINDERMAN ITZHAK (IL) 1997-08-21 WO claimed
US-5646134-A INHIBITING BONE RESORPTION MERCK & CO., INC. (US) 1997-07-08 US claimed
WO-1996035407-A1 PREVENTION OF TOOTH LOSS BY THE ADMINISTRATION OF ALENDRONATE OR ITS SALTS MERCK & CO., INC. (US) 1996-11-14 WO claimed